AERI - Aerie Pharmaceuticals, Inc.

NasdaqGS - NasdaqGS Real-time price. Currency in USD
20.51
-0.74 (-3.48%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous close21.25
Open21.02
Bid20.53 x 1200
Ask20.54 x 800
Day's range20.09 - 21.42
52-week range17.51 - 60.04
Volume1,616,087
Avg. volume1,283,673
Market cap942.213M
Beta (3Y monthly)0.75
PE ratio (TTM)N/A
EPS (TTM)-5.17
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est63.11
Trade prices are not sourced from all markets
  • Business Wire

    Aerie Pharmaceuticals Announces Appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Charlene E. Davis, Esq., as Vice President and Chief Compliance Officer, reporting to John LaRocca, Aerie’s General Counsel. Ms. Davis will oversee the world wide compliance and data privacy functions for the Company.

  • Business Wire

    Aerie Pharmaceuticals to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that Richard Rubino, Chief Financial Officer, will present in a fireside discussion at the 2019 Cantor Fitzgerald Global Healthcare Conference on Wednesday, October 2, 2019 at 3:35 p.m. Eastern Time in New York, NY. Aerie is an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye.

  • Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa
    Zacks

    Aerie Secures Positive CHMP Opinion for Eye Drug Rhokiinsa

    The CHMP recommends Aerie's (AERI) marketing application for Rhokiinsa to reduce elevated intraocular pressure in adult patients with open-angle glaucoma or ocular hypertension.

  • Business Wire

    Aerie Pharmaceuticals Receives Positive CHMP Opinion for Rhokiinsa® in the European Union

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of the marketing authorisation application (MAA) for Rhokiinsa® (netarsudil ophthalmic solution) 0.02%. The recommended indication is the reduction of elevated intraocular pressure in adult patients with primary open-angle glaucoma or ocular hypertension. The CHMP positive opinion is a scientific recommendation for marketing authorisation referred to the European Commission for a final decision on the Company’s MAA.

  • Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money?
    Simply Wall St.

    Will Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Need To Raise More Money?

    As the US$994m market cap Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) released another year of negative earnings...

  • Business Wire

    Aerie Pharmaceuticals Submits Prior Approval Supplement to the U.S. Food and Drug Administration to Allow Production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% in its Athlone Ireland Facility

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the submission of a prior approval supplement (PAS) to the U.S. Food and Drug Administration (FDA). If approved, the PAS will permit production of Rocklatan® (netarsudil and latanoprost ophthalmic solution) 0.02%/0.005% for sale in the United States in Aerie’s new manufacturing plant in Athlone, Ireland.

  • Business Wire

    Aerie Pharmaceuticals Announces Full Exercise by Initial Purchasers of Option to Purchase Additional $41.25 Million Aggregate Principal Amount of Aerie’s 1.50% Convertible Senior Notes Due 2024

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that the initial purchasers of the previously announced offering of Aerie’s 1.50% Convertible Senior Notes due 2024 (the “notes”) in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended, have elected to fully exercise their option to purchase an additional $41.25 million aggregate principal amount of the notes. The settlement of the sale of additional notes pursuant to the option is expected to occur on September 12, 2019, subject to customary closing conditions.

  • Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound?
    Zacks

    Aerie (AERI) Down 19.7% Since Last Earnings Report: Can It Rebound?

    Aerie (AERI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Business Wire

    Aerie Pharmaceuticals Upsizes and Prices Private Offering of $275 Million 1.50% Convertible Senior Notes Due 2024

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced that it has priced $275 million aggregate principal amount of its 1.50% convertible senior notes due 2024 (the “notes”). The offering was increased to $275 million aggregate principal amount of notes from the previously announced offering size of $250 million aggregate principal amount of notes. Aerie has also granted the initial purchasers of the notes a 13-day option to purchase up to an additional $41.25 million aggregate principal amount of the notes.

  • Business Wire

    Aerie Pharmaceuticals to Offer $250 Million Convertible Senior Notes Due 2024

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye, today announced that it proposes to offer $250 million aggregate principal amount of its convertible senior notes due 2024 (the “notes”), subject to market conditions and other factors. The notes are to be offered in a private offering to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended. Aerie also intends to grant to the initial purchasers of the notes a 13-day option to purchase up to an additional $37.5 million aggregate principal amount of the notes.

  • Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance
    Zacks

    Aerie (AERI) Beats on Q2 Earnings & Sales, Lowers Guidance

    Aerie (AERI) lowers its annual sales guidance and reports a narrower loss in Q2.

  • Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability
    Simply Wall St.

    Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI) Path To Profitability

    Aerie Pharmaceuticals, Inc.'s (NASDAQ:AERI): Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company...

  • Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript
    Motley Fool

    Aerie Pharmaceuticals, Inc. (AERI) Q2 2019 Earnings Call Transcript

    AERI earnings call for the period ending June 30, 2019.

  • Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates
    Zacks

    Aerie Pharmaceuticals (AERI) Reports Q2 Loss, Tops Revenue Estimates

    Aerie (AERI) delivered earnings and revenue surprises of 8.05% and 8.47%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know
    Zacks

    Will Aerie Pharmaceuticals (AERI) Report Negative Earnings Next Week? What You Should Know

    Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Allergan Announces FDA Acceptance of Glaucoma Candidate NDA
    Zacks

    Allergan Announces FDA Acceptance of Glaucoma Candidate NDA

    The FDA accepts Allergan's (AGN) NDA seeking approval for Bimatoprost SR. A decision is expected in first half of 2020.

  • Aerie Completes Enrollment Under Rhopressa Study in Japan
    Zacks

    Aerie Completes Enrollment Under Rhopressa Study in Japan

    Aerie (AERI) completes enrollment in mid-stage study on Rhopressa in Japan much ahead of schedule.

  • Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza
    Zacks

    Ocular (OCUL) Gets FDA Nod for Label Expansion of Dextenza

    Ocular (OCUL) clinches the FDA approval for the label expansion of Dextenza to treat ocular inflammation following ophthalmic surgery.

  • Business Wire

    Aerie Pharmaceuticals Announces Appointment of Jeffrey Calabrese, CPA, as Director of Accounting

    Aerie Pharmaceuticals, Inc. (AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye today announced the appointment of Jeffrey Calabrese, CPA, as Director of Accounting, reporting to Christopher Staten, Aerie’s Vice President of Finance. Mr. Calabrese will lead external financial reporting, technical accounting and equity accounting. In connection with his acceptance of the position as Director of Accounting, Mr. Calabrese will receive awards totaling 14,400 stock options that will vest over 4 years, with 25% vesting on the first anniversary of the hire date and the remainder vesting ratably on each of the subsequent 36 monthly anniversaries of the hire date.

  • Business Wire

    Aerie Pharmaceuticals to Present at Two Upcoming Investor Conferences

    Aerie Pharmaceuticals, Inc. , an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the trea

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more